查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1916714

癌症免疫疗法市场预测至2032年：按类型、治疗环境、技术、应用、最终用户和地区分類的全球分析

Cancer Immunotherapy Market Forecasts to 2032 - Global Analysis By Type, Treatment Setting, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 预测，全球癌症免疫疗法市场预计到 2025 年将达到 1,406.3 亿美元，到 2032 年将达到 2,505.5 亿美元，预测期内复合年增长率为 8.6%。

癌症免疫疗法是一种利用人体自体免疫系统对抗癌症的治疗策略。它并非直接攻击肿瘤，而是增强免疫细胞辨识和摧毁癌细胞的能力。治疗方法包括免疫查核点抑制剂、癌症疫苗、单株抗体和过继性细胞疗法。透过针对肿瘤特异性抗原并恢復免疫功能，免疫疗法可以产生持久的疗效，降低復发率，并提高存活率。这种个人化、标靶治疗代表了肿瘤学领域的变革性转折点，为难治性癌症患者带来了新的希望。

全球癌症负担日益加重

全球癌症发生率的不断攀升是癌症免疫疗法市场的主要驱动力。各种恶性肿瘤的日益流行，加上人口老化和生活方式相关的风险因素，使得人们对先进治疗方法的需求显着增加。由于传统治疗方法往往效果不佳，患者和医疗机构开始转向具有标靶性和持久疗效的免疫疗法。日益沉重的癌症负担促使製药公司加强研发投入，加速了全球市场的扩张。

医疗成本不断上涨

高昂的治疗费用是癌症免疫疗法普及的一大障碍。包括免疫查核点抑制剂和个人化细胞疗法在内的先进治疗方法，需要复杂的生产过程、专门的给药方法和持续的监测。许多患者，尤其是在中低收入地区，面临经济负担，这限制了他们获得和接受治疗的机会。此外，保险覆盖范围和报销方面的挑战进一步加重了治疗的经济负担。这些经济障碍减缓了市场渗透速度，并对全球肿瘤领域的永续发展构成了重大挑战。

免疫肿瘤学的进展

免疫肿瘤学的持续进步为市场带来了巨大的机会。新一代免疫查核点抑制剂、基因改造T细胞和联合治疗等新型疗法正在提高疗效并拓展治疗适应症。肿瘤特异性抗原和个人化治疗策略的研究进展正在改善患者的预后。此外，生技公司与大型製药公司之间日益密切的合作正在加速药物研发。这些创新有望创造新的收入来源并扩大市场规模。

监理和核准问题

监管和核准的挑战对市场构成重大威胁。复杂的临床试验要求、严格的安全性和有效性标准，以及不同地区法规结构，都可能延缓产品核可。这些障碍会增加研发成本和週期，进而影响整体盈利和市场准入。核准后的监测和合规义务进一步加剧了商业化进程的复杂性。监管的不确定性，加上不断变化的安全指南，可能会抑制创新，延缓产品应用，并为全球投资新型免疫疗法的公司带来风险。

新冠疫情的影响：

新冠疫情导致临床试验延长、医院就诊量减少、择期治疗受限，严重扰乱了市场。供应链中断影响了关键生物製药的生产和分销。然而，疫情也加速了远端医疗的普及，并凸显了免疫治疗方法的必要性。製药公司透过实施远端监测和安全通讯协定来应对疫情，从而减轻了长期影响。总体而言，儘管疫情初期的衝击减缓了市场成长，但疫情后的復苏以及对免疫疗法的重新关注预计将在未来几年推动市场强劲扩张。

预计在预测期内，细胞激素细分市场将占据最大的市场份额。

由于细胞激素在刺激抗肿瘤免疫反应中发挥至关重要的作用，预计在预测期内，细胞激素领域将占据最大的市场份额。细胞激素能够活化T细胞和自然杀手细胞，因此在标靶癌症治疗中不可或缺。不断增加的研究、良好的临床结果以及基于细胞激素治疗方法的核准，都在推动市场成长。此外，与其他免疫疗法药物联合治疗时疗效的提升，也使细胞激素成为全球创新癌症治疗策略的基石。

预计在预测期内，乳癌细分市场将呈现最高的复合年增长率。

由于公众意识的提高和早期诊断的普及，以及对先进治疗方法需求的不断增长，预计乳癌领域在预测期内将呈现最高的成长率。包括查核点抑制剂和个人化疫苗在内的免疫疗法已在乳癌患者中展现出令人鼓舞的临床效果。生物标记识别和联合治疗策略的进步进一步提高了治疗效果。因此，该领域的医药投资和研发活动正在增加，推动市场快速成长，并为全球患者带来新的希望。

占比最大的地区：

预计亚太地区将在整个预测期内保持最大的市场份额，这主要得益于癌症发病率的上升以及政府为改善先进疗法的可及性而采取的主导。人们对创新治疗方法的认知度和接受度不断提高，加上庞大的患者群体，共同创造了巨大的市场潜力。跨国製药公司与当地企业之间的策略合作进一步巩固了其市场地位，使亚太地区成为癌症免疫疗法持续成长的关键区域。

年复合成长率最高的地区：

在预测期内，北美预计将实现最高的复合年增长率，这主要得益于高额的研发投入和对创新治疗方法的强有力的监管支持。公众意识的广泛提高、早期诊断的普及以及有利的报销政策正在加速疗法的推广应用。大型製药公司的存在和广泛的临床试验活动也推动了快速成长。包括个人化和联合免疫疗法在内的前沿研究正在推动新型治疗方法的开发，使北美成为癌症免疫疗法领域高成长、创新主导的中心。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，提供主要国家的市场估算和预测以及复合年增长率（註：可行性需确认）。
  • 竞争标竿分析
    • 根据主要企业的产品系列、地理覆盖范围和策略联盟进行基准分析

目录

第一章执行摘要

第二章 前言

  • 概括
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第五章 全球癌症免疫疗法市场（按类型划分）

  • 免疫查核点抑制剂
    • PD-1抑制剂
    • PD-L1抑制剂
    • CTLA-4抑制剂
  • 单株抗体
  • 癌症疫苗
  • 过继性细胞转移疗法
    • CAR-T细胞疗法
    • TCR疗法
    • 肿瘤浸润淋巴细胞（TILs）
  • 细胞激素
  • 溶瘤病毒疗法

6. 全球癌症免疫疗法市场（依治疗场所划分）

  • 医院
  • 专科诊所
  • 门诊手术中心
  • 家庭医疗保健

7. 全球癌症免疫疗法市场（依技术划分）

  • 基因编辑与基因工程
  • 奈米技术在免疫疗法的应用
  • 生物标记伴随诊断
  • 其他技术

第八章 全球癌症免疫疗法市场（按应用划分）

  • 乳癌
  • 肺癌
  • 黑色素瘤
  • 大肠直肠癌
  • 摄护腺癌
  • 骨髓恶性肿瘤
  • 其他用途

第九章 全球癌症免疫疗法市场（按最终用户划分）

  • 研究和学术机构
  • 诊断检查室
  • 其他最终用户

第十章 全球癌症免疫疗法市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章 企业概况

  • Amgen Inc.
  • AbbVie Inc.
  • AstraZeneca Plc
  • Johnson &Johnson
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • Merck &Co., Inc.
  • Seagen Inc.
  • F. Hoffmann-La Roche Ltd
  • BeiGene Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • GlaxoSmithKline Plc（GSK）
Product Code: SMRC33287

According to Stratistics MRC, the Global Cancer Immunotherapy Market is accounted for $140.63 billion in 2025 and is expected to reach $250.55 billion by 2032 growing at a CAGR of 8.6% during the forecast period. Cancer immunotherapy is a treatment strategy that leverages the body's immune system to fight cancer. Instead of directly attacking tumors, it enhances immune cells' ability to recognize and destroy cancer cells. Approaches include immune checkpoint inhibitors, cancer vaccines, monoclonal antibodies, and adoptive cell therapies. By targeting tumor-specific antigens and restoring immune function, immunotherapy can provide durable responses, reduce relapse, and improve survival. This personalized, targeted approach represents a transformative shift in oncology, offering new hope for patients with difficult to treat cancers.

Market Dynamics:

Driver:

Rising Global Cancer Burden

The increasing incidence of cancer worldwide is a key driver for the cancer immunotherapy market. Rising prevalence of various malignancies, coupled with aging populations and lifestyle-related risk factors, is creating significant demand for advanced treatments. As conventional therapies often fall short in efficacy, patients and healthcare providers are turning to immunotherapy solutions that offer targeted, durable responses. This growing cancer burden is prompting pharmaceutical companies to invest heavily in research and development, accelerating market expansion globally.

Restraint:

High Treatment Costs

High treatment costs pose a significant restraint to the adoption of cancer immunotherapy. Advanced therapies, including immune checkpoint inhibitors and personalized cell-based treatments, require complex manufacturing, specialized administration, and ongoing monitoring. Many patients, especially in low- and middle-income regions, face financial barriers, limiting access and adoption. Additionally, insurance coverage and reimbursement challenges further restrict affordability. These economic hurdles slow market penetration, posing a critical challenge to sustainable growth in the global oncology landscape.

Opportunity:

Advancements in Immuno-Oncology

Ongoing advancements in immuno-oncology present significant opportunities for the market. Novel approaches, including next-generation immune checkpoint inhibitors, engineered T-cells, and combination therapies, are enhancing efficacy and expanding treatment indications. Research breakthroughs in tumor-specific antigens and personalized therapy strategies are improving patient outcomes. Additionally, increasing collaboration between biotech companies and pharmaceutical giants is accelerating drug discovery. These innovations are expected to create new revenue streams and expand the market.

Threat:

Regulatory & Approval Challenges

Regulatory and approval challenges are a major threat to the market. Complex clinical trial requirements, stringent safety and efficacy standards, and varying regulatory frameworks across regions can delay product approvals. These hurdles increase development costs and timelines, affecting overall profitability and market entry. Post-approval monitoring and compliance obligations further complicate commercialization. Regulatory uncertainty, combined with evolving safety guidelines can hinder innovation, slow adoption, and pose risks to companies investing in novel immunotherapy therapies worldwide.

Covid-19 Impact:

The COVID-19 pandemic disrupted the market by delaying clinical trials, reducing hospital visits, and limiting elective treatments. Supply chain interruptions affected the production and distribution of critical biologics. However, the pandemic also accelerated telemedicine adoption and highlighted the need for immune-based therapies. Pharmaceutical companies adapted by implementing remote monitoring and safety protocols, mitigating long-term impact. Overall, while initial disruptions slowed growth, post-pandemic recovery and renewed focus on immunotherapies have positioned the market for strong expansion in the coming years.

The cytokines segment is expected to be the largest during the forecast period

The cytokines segment is expected to account for the largest market share during the forecast period as they crucial role in stimulating immune responses against tumors. Their ability to activate T-cells and natural killer cells makes them vital in targeted cancer therapy. Increasing research, favorable clinical outcomes, and approvals for cytokine-based therapies are driving market growth. Furthermore, combination therapies with other immunotherapeutics enhance efficacy, positioning cytokines as a cornerstone of innovative oncology treatment strategies globally.

The breast cancer segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the breast cancer segment is predicted to witness the highest growth rate, due to growing awareness, and early diagnosis are increasing demand for advanced therapies. Immunotherapy approaches, including checkpoint inhibitors and personalized vaccines, are showing promising clinical outcomes in breast cancer patients. Advances in biomarker identification and combination therapy strategies are further enhancing treatment efficacy. As a result, pharmaceutical investment and research activity are intensifying in this segment, driving rapid market growth and offering new hope to patients globally.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to growing cancer prevalence, and increasing government initiatives to improve access to advanced therapies are key contributors. Rising awareness and adoption of innovative treatments, coupled with a large patient population, create significant market potential. Strategic partnerships between multinational pharmaceutical companies and local firms further strengthen market presence, making Asia Pacific a critical region for sustained growth in cancer immunotherapy.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to high R&D investment, and strong regulatory support for innovative therapies. Widespread awareness, early diagnosis, and favorable reimbursement policies accelerate adoption. The presence of leading pharmaceutical companies and extensive clinical trial activity also fuels rapid growth. Cutting-edge research, including personalized and combination immunotherapies, is driving the development of novel treatments, positioning North America as a high-growth, innovation-driven hub for cancer immunotherapy.

Key players in the market

Some of the key players in Cancer Immunotherapy Market include Amgen Inc., AbbVie Inc., AstraZeneca Plc, Johnson & Johnson, Bristol-Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Seagen Inc., F. Hoffmann-La Roche Ltd, BeiGene Ltd., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Novartis AG, Eli Lilly and Company and GlaxoSmithKline Plc (GSK).

Key Developments:

In January 2026, Cartography Biosciences and Pfizer forged a multi year pact to unearth tumor selective antigens using Cartography's pioneering ATLAS and SUMMIT platforms, aiming to fuel next generation precision oncology with shared discovery and development efforts.

In December 2025, Pfizer has struck an exclusive global collaboration and license deal with YaoPharma, a Shanghai Fosun subsidiary, to develop, manufacture, and commercialize YP05002, an oral small molecule GLP 1 receptor agonist now in Phase I for chronic weight management.

Types Covered:

  • Immune Checkpoint Inhibitors
  • Monoclonal Antibodies
  • Cancer Vaccines
  • Adoptive Cell Transfer Therapy
  • Cytokines
  • Oncolytic Virus Therapy

Treatment Settings Covered:

  • Hospital
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home Healthcare

Technologies Covered:

  • Gene Editing & Engineering
  • Nanotechnology in Immunotherapy
  • Biomarker & Companion Diagnostics
  • Other Technologies

Applications Covered:

  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Prostate Cancer
  • Hematologic Malignancies
  • Other Applications

End Users Covered:

  • Research & Academic Institutes
  • Diagnostic Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Immunotherapy Market, By Type

  • 5.1 Introduction
  • 5.2 Immune Checkpoint Inhibitors
    • 5.2.1 PD-1 Inhibitors
    • 5.2.2 PD-L1 Inhibitors
    • 5.2.3 CTLA-4 Inhibitors
  • 5.3 Monoclonal Antibodies
  • 5.4 Cancer Vaccines
  • 5.5 Adoptive Cell Transfer Therapy
    • 5.5.1 CAR-T Cell Therapy
    • 5.5.2 TCR Therapy
    • 5.5.3 Tumor-Infiltrating Lymphocytes (TILs)
  • 5.6 Cytokines
  • 5.7 Oncolytic Virus Therapy

6 Global Cancer Immunotherapy Market, By Treatment Setting

  • 6.1 Introduction
  • 6.2 Hospital
  • 6.3 Specialty Clinics
  • 6.4 Ambulatory Surgical Centers
  • 6.5 Home Healthcare

7 Global Cancer Immunotherapy Market, By Technology

  • 7.1 Introduction
  • 7.2 Gene Editing & Engineering
  • 7.3 Nanotechnology in Immunotherapy
  • 7.4 Biomarker & Companion Diagnostics
  • 7.5 Other Technologies

8 Global Cancer Immunotherapy Market, By Application

  • 8.1 Introduction
  • 8.2 Breast Cancer
  • 8.3 Lung Cancer
  • 8.4 Melanoma
  • 8.5 Colorectal Cancer
  • 8.6 Prostate Cancer
  • 8.7 Hematologic Malignancies
  • 8.8 Other Applications

9 Global Cancer Immunotherapy Market, By End User

  • 9.1 Introduction
  • 9.2 Research & Academic Institutes
  • 9.3 Diagnostic Laboratories
  • 9.4 Other End Users

10 Global Cancer Immunotherapy Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Amgen Inc.
  • 12.2 AbbVie Inc.
  • 12.3 AstraZeneca Plc
  • 12.4 Johnson & Johnson
  • 12.5 Bristol-Myers Squibb Company
  • 12.6 Sanofi S.A.
  • 12.7 Merck & Co., Inc.
  • 12.8 Seagen Inc.
  • 12.9 F. Hoffmann-La Roche Ltd
  • 12.10 BeiGene Ltd.
  • 12.11 Pfizer Inc.
  • 12.12 Regeneron Pharmaceuticals, Inc.
  • 12.13 Novartis AG
  • 12.14 Eli Lilly and Company
  • 12.15 GlaxoSmithKline Plc (GSK)

List of Tables

  • Table 1 Global Cancer Immunotherapy Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Cancer Immunotherapy Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Cancer Immunotherapy Market Outlook, By Immune Checkpoint Inhibitors (2024-2032) ($MN)
  • Table 4 Global Cancer Immunotherapy Market Outlook, By PD-1 Inhibitors (2024-2032) ($MN)
  • Table 5 Global Cancer Immunotherapy Market Outlook, By PD-L1 Inhibitors (2024-2032) ($MN)
  • Table 6 Global Cancer Immunotherapy Market Outlook, By CTLA-4 Inhibitors (2024-2032) ($MN)
  • Table 7 Global Cancer Immunotherapy Market Outlook, By Monoclonal Antibodies (2024-2032) ($MN)
  • Table 8 Global Cancer Immunotherapy Market Outlook, By Cancer Vaccines (2024-2032) ($MN)
  • Table 9 Global Cancer Immunotherapy Market Outlook, By Adoptive Cell Transfer Therapy (2024-2032) ($MN)
  • Table 10 Global Cancer Immunotherapy Market Outlook, By CAR-T Cell Therapy (2024-2032) ($MN)
  • Table 11 Global Cancer Immunotherapy Market Outlook, By TCR Therapy (2024-2032) ($MN)
  • Table 12 Global Cancer Immunotherapy Market Outlook, By Tumor-Infiltrating Lymphocytes (TILs) (2024-2032) ($MN)
  • Table 13 Global Cancer Immunotherapy Market Outlook, By Cytokines (2024-2032) ($MN)
  • Table 14 Global Cancer Immunotherapy Market Outlook, By Oncolytic Virus Therapy (2024-2032) ($MN)
  • Table 15 Global Cancer Immunotherapy Market Outlook, By Treatment Setting (2024-2032) ($MN)
  • Table 16 Global Cancer Immunotherapy Market Outlook, By Hospital (2024-2032) ($MN)
  • Table 17 Global Cancer Immunotherapy Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 18 Global Cancer Immunotherapy Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 19 Global Cancer Immunotherapy Market Outlook, By Home Healthcare (2024-2032) ($MN)
  • Table 20 Global Cancer Immunotherapy Market Outlook, By Technology (2024-2032) ($MN)
  • Table 21 Global Cancer Immunotherapy Market Outlook, By Gene Editing & Engineering (2024-2032) ($MN)
  • Table 22 Global Cancer Immunotherapy Market Outlook, By Nanotechnology in Immunotherapy (2024-2032) ($MN)
  • Table 23 Global Cancer Immunotherapy Market Outlook, By Biomarker & Companion Diagnostics (2024-2032) ($MN)
  • Table 24 Global Cancer Immunotherapy Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 25 Global Cancer Immunotherapy Market Outlook, By Application (2024-2032) ($MN)
  • Table 26 Global Cancer Immunotherapy Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 27 Global Cancer Immunotherapy Market Outlook, By Lung Cancer (2024-2032) ($MN)
  • Table 28 Global Cancer Immunotherapy Market Outlook, By Melanoma (2024-2032) ($MN)
  • Table 29 Global Cancer Immunotherapy Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
  • Table 30 Global Cancer Immunotherapy Market Outlook, By Prostate Cancer (2024-2032) ($MN)
  • Table 31 Global Cancer Immunotherapy Market Outlook, By Hematologic Malignancies (2024-2032) ($MN)
  • Table 32 Global Cancer Immunotherapy Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 33 Global Cancer Immunotherapy Market Outlook, By End User (2024-2032) ($MN)
  • Table 34 Global Cancer Immunotherapy Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 35 Global Cancer Immunotherapy Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 36 Global Cancer Immunotherapy Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.